Ed Arce
Stock Analyst at HC Wainwright & Co.
(2.27)
# 1,222
Out of 4,479 analysts
327
Total ratings
36.22%
Success rate
-1.21%
Average return
Main Sectors:
Top Industries:
35 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Reiterates: Buy | $66 | $34.16 | +93.21% | 25 | Jun 28, 2024 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $4.5 | $0.54 | +733.33% | 17 | Jun 25, 2024 | |
| ITRM Iterum Therapeutics | Reiterates: Buy | $6 | $1.10 | +447.95% | 10 | Jun 21, 2024 | |
| ASMB Assembly Biosciences | Reiterates: Neutral | n/a | $13.24 | - | 5 | Jun 20, 2024 | |
| SGMT Sagimet Biosciences | Reiterates: Buy | $32 | $3.16 | +912.66% | 5 | Jun 14, 2024 | |
| GNFT Genfit | Maintains: Buy | $11 → $13 | $4.00 | +225.00% | 13 | Jun 11, 2024 | |
| ETNB 89bio | Reiterates: Buy | $29 | $7.76 | +273.71% | 18 | Jun 11, 2024 | |
| AKRO Akero Therapeutics | Reiterates: Buy | $50 | $23.16 | +115.89% | 16 | Jun 11, 2024 | |
| ABUS Arbutus Biopharma | Reiterates: Buy | $5 | $3.12 | +60.26% | 15 | Jun 7, 2024 | |
| PLRX Pliant Therapeutics | Reiterates: Buy | $36 | $10.86 | +231.49% | 16 | Jun 7, 2024 | |
| DRRX DURECT | Reiterates: Neutral | n/a | $1.31 | - | 9 | May 22, 2024 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $12 | $2.14 | +460.75% | 11 | May 16, 2024 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.92 | +554.81% | 3 | May 15, 2024 | |
| TERN Terns Pharmaceuticals | Reiterates: Neutral | $5.5 | $6.85 | -19.71% | 9 | May 14, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $425 → $390 | $279.31 | +39.63% | 12 | May 8, 2024 | |
| TVTX Travere Therapeutics | Reiterates: Buy | $19 | $8.28 | +129.47% | 16 | May 7, 2024 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $28 → $27 | $13.07 | +106.58% | 7 | May 7, 2024 | |
| GALT Galectin Therapeutics | Reiterates: Buy | $11 | $2.35 | +368.09% | 9 | Apr 9, 2024 | |
| CDTX Cidara Therapeutics | Maintains: Buy | $120 | $12.04 | +896.68% | 17 | Apr 8, 2024 | |
| IVA Inventiva | Reiterates: Buy | $22 | $2.92 | +654.72% | 11 | Apr 1, 2024 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $5 → $6 | $0.99 | +503.38% | 20 | Mar 28, 2024 | |
| ZVSA ZyVersa Therapeutics | Reiterates: Buy | $240 | $3.61 | +6,543.97% | 4 | Mar 26, 2024 | |
| SYBX Synlogic | Upgrades: Neutral | n/a | $1.49 | - | 8 | Mar 20, 2024 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $23.66 | +153.59% | 17 | Mar 8, 2024 | |
| AUPH Aurinia Pharmaceuticals | Reiterates: Buy | $13 | $5.49 | +136.79% | 11 | Mar 1, 2024 | |
| VERA Vera Therapeutics | Reiterates: Buy | $25 | $36.29 | -31.11% | 7 | Dec 27, 2023 | |
| ARDX Ardelyx | Maintains: Buy | $9 → $11 | $7.57 | +45.31% | 3 | Nov 1, 2023 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Buy | $82 | $41.12 | +99.42% | 2 | Aug 1, 2023 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Neutral | n/a | $0.28 | - | 2 | May 3, 2022 | |
| ATXI Avenue Therapeutics | Maintains: Buy | $13,500 → $14,625 | $3.40 | +430,047.06% | 2 | May 12, 2020 | |
| SMMT Summit Therapeutics | Initiates: Buy | n/a | $8.14 | - | 1 | Mar 19, 2020 | |
| TRVN Trevena | Downgrades: Neutral | n/a | $0.21 | - | 3 | Nov 5, 2018 | |
| VKTX Viking Therapeutics | Assumes: Buy | n/a | $55.32 | - | 1 | Nov 10, 2017 | |
| COLL Collegium Pharmaceutical | Initiates: Buy | n/a | $32.62 | - | 1 | Sep 11, 2017 | |
| AVIR Atea Pharmaceuticals | Downgrades: Neutral | n/a | $3.37 | - | 1 | Feb 15, 2017 |
Mirum Pharmaceuticals
Jun 28, 2024
Reiterates: Buy
Price Target: $66
Current: $34.16
Upside: +93.21%
Unicycive Therapeutics
Jun 25, 2024
Reiterates: Buy
Price Target: $4.5
Current: $0.54
Upside: +733.33%
Iterum Therapeutics
Jun 21, 2024
Reiterates: Buy
Price Target: $6
Current: $1.10
Upside: +447.95%
Assembly Biosciences
Jun 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $13.24
Upside: -
Sagimet Biosciences
Jun 14, 2024
Reiterates: Buy
Price Target: $32
Current: $3.16
Upside: +912.66%
Genfit
Jun 11, 2024
Maintains: Buy
Price Target: $11 → $13
Current: $4.00
Upside: +225.00%
89bio
Jun 11, 2024
Reiterates: Buy
Price Target: $29
Current: $7.76
Upside: +273.71%
Akero Therapeutics
Jun 11, 2024
Reiterates: Buy
Price Target: $50
Current: $23.16
Upside: +115.89%
Arbutus Biopharma
Jun 7, 2024
Reiterates: Buy
Price Target: $5
Current: $3.12
Upside: +60.26%
Pliant Therapeutics
Jun 7, 2024
Reiterates: Buy
Price Target: $36
Current: $10.86
Upside: +231.49%
DURECT
May 22, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.31
Upside: -
Acurx Pharmaceuticals
May 16, 2024
Reiterates: Buy
Price Target: $12
Current: $2.14
Upside: +460.75%
Talphera
May 15, 2024
Reiterates: Buy
Price Target: $6
Current: $0.92
Upside: +554.81%
Terns Pharmaceuticals
May 14, 2024
Reiterates: Neutral
Price Target: $5.5
Current: $6.85
Upside: -19.71%
Madrigal Pharmaceuticals
May 8, 2024
Maintains: Buy
Price Target: $425 → $390
Current: $279.31
Upside: +39.63%
Travere Therapeutics
May 7, 2024
Reiterates: Buy
Price Target: $19
Current: $8.28
Upside: +129.47%
Enanta Pharmaceuticals
May 7, 2024
Maintains: Buy
Price Target: $28 → $27
Current: $13.07
Upside: +106.58%
Galectin Therapeutics
Apr 9, 2024
Reiterates: Buy
Price Target: $11
Current: $2.35
Upside: +368.09%
Cidara Therapeutics
Apr 8, 2024
Maintains: Buy
Price Target: $120
Current: $12.04
Upside: +896.68%
Inventiva
Apr 1, 2024
Reiterates: Buy
Price Target: $22
Current: $2.92
Upside: +654.72%
Akebia Therapeutics
Mar 28, 2024
Maintains: Buy
Price Target: $5 → $6
Current: $0.99
Upside: +503.38%
ZyVersa Therapeutics
Mar 26, 2024
Reiterates: Buy
Price Target: $240
Current: $3.61
Upside: +6,543.97%
Synlogic
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.49
Upside: -
Arcturus Therapeutics Holdings
Mar 8, 2024
Reiterates: Buy
Price Target: $60
Current: $23.66
Upside: +153.59%
Aurinia Pharmaceuticals
Mar 1, 2024
Reiterates: Buy
Price Target: $13
Current: $5.49
Upside: +136.79%
Vera Therapeutics
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $36.29
Upside: -31.11%
Ardelyx
Nov 1, 2023
Maintains: Buy
Price Target: $9 → $11
Current: $7.57
Upside: +45.31%
Ultragenyx Pharmaceutical
Aug 1, 2023
Reiterates: Buy
Price Target: $82
Current: $41.12
Upside: +99.42%
Galmed Pharmaceuticals
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.28
Upside: -
Avenue Therapeutics
May 12, 2020
Maintains: Buy
Price Target: $13,500 → $14,625
Current: $3.40
Upside: +430,047.06%
Summit Therapeutics
Mar 19, 2020
Initiates: Buy
Price Target: n/a
Current: $8.14
Upside: -
Trevena
Nov 5, 2018
Downgrades: Neutral
Price Target: n/a
Current: $0.21
Upside: -
Viking Therapeutics
Nov 10, 2017
Assumes: Buy
Price Target: n/a
Current: $55.32
Upside: -
Collegium Pharmaceutical
Sep 11, 2017
Initiates: Buy
Price Target: n/a
Current: $32.62
Upside: -
Atea Pharmaceuticals
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.37
Upside: -